2022 spells change for EU pharmaceutical legislation : vimar

With pharmaceutical regulation currently under review across Europe, Maarten Meulenbelt, Partner at Sidley Austin LLP, discusses some of the more controversial amendments under consideration.

Related Keywords

Germany , United Kingdom , Dolon , Rhôalpes , France , Italy , Spain , Brussels , Bruxelles Capitale , Belgium , London , City Of , Amsterdam , Noord Holland , Netherlands , The Council , Hannah Balfour , Maarten Meulenbelt , Dolon Ltd , Sidley Austin , Eu Pharmaceuticals Strategy , European Parliament , European Commission , Office Of Health Economics , European Federation Of Pharmaceutical Industry Associations , Partner At Sidley Austin , United Kingdom Office Of Health Economics , European Union , European Medicines Agency Text , European Pharmaceutical Review , Member States , Net Present Value , Health Economics , European Federation , Pharmaceutical Industry Associations , Orphan Drug Regulation , Orphan Drug , Council Of Ministers , Science Writer , European Pharmaceutical , European Medicines Agency , Gupta Strategists , Financial Challenges , Developing Orphan Medicinal , European Legislation Tackle ,